Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation - Archive ouverte HAL Access content directly
Journal Articles Oncogene Year : 2022

Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation

(1) , (1) , (1) , (1) , (2, 1) , (3, 1) , (4, 1) , (5, 1) , (5, 1) , (5, 1) , (6) , (7) , (5) , (6) , (8, 7) , (7, 8) , (7, 8) , (9) , (1) , (5, 1)
1
2
3
4
5
6
7
8
9
Margaux Sala
Arnaud Jabouille
Jean-William Dupuy
Violaine Moreau

Abstract

Combined therapy with anti-BRAF plus anti-MEK is currently used as first-line treatment of patients with metastatic melanomas harboring the somatic BRAF V600E mutation. However, the main issue with targeted therapy is the acquisition of tumor cell resistance. In a majority of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype switching makes melanoma cells more invasive. Its signature is characterized by MITF low, AXL high, and actin cytoskeleton reorganization through RhoA activation. In parallel of this phenotype switching phase, the resistant cells exhibit an anarchic cell proliferation due to hyper-activation of the MAP kinase pathway. We show that a majority of human melanoma overexpress discoidin domain receptor 2 (DDR2) after treatment. The same result was found in resistant cell lines presenting phenotype switching compared to the corresponding sensitive cell lines. We demonstrate that DDR2 inhibition induces a decrease in AXL expression and reduces stress fiber formation in resistant melanoma cell lines. In this phenotype switching context, we report that DDR2 control cell and tumor proliferation through the MAP kinase pathway in resistant cells in vitro and in vivo. Therefore, inhibition of DDR2 could be a new and promising strategy for countering this resistance mechanism.
Not file

Dates and versions

inserm-03791558 , version 1 (29-09-2022)

Identifiers

Cite

Margaux Sala, Nathalie Allain, Mélanie Moreau, Arnaud Jabouille, Elodie Henriet, et al.. Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation. Oncogene, 2022, 41 (18), pp.2571-2586. ⟨10.1038/s41388-022-02266-1⟩. ⟨inserm-03791558⟩
6 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More